An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)

NCT01224093 · clinicaltrials.gov ↗

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG: Chemotherapy
DRUG: rituximab [MabThera/Rituxan]

Sponsor

Hoffmann-La Roche